Are CDK4/6 Inhibitors Transforming Breast Cancer Treatment?
Source: Breast Cancer Research Foundation Science News CDK4/6 inhibitors are a new class of drugs...
WHAT'S UP IN
Cyclin-dependent kinase 4
Ribociclib improves progression-free survival in advanced breast cancer
The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves...
ESMO 2016: Ribociclib Improves Progression-Free Survival in Advanced Breast Cancer
The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improved...
Novartis’ HR+/HER2- advanced breast cancer trial gives superior progression-free survival
You are here: Home » News » Industry news » Novartis’ HR+/HER2- advanced...
